Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
12,217 total articles
BYDDF ($11.07) is the easiest way for U.S. traders to express a bullish view on BYD's global EV momentum. Technicals show recent consolidation near multi-month support, short interest has pulled back from extreme levels, and investor confidence tied to long-term strategic investors provides a valuation floor. This is a trade idea for a measured lon…
Trilogy Metals just moved from capital-starved developer toward a de-risked project because the U.S. government took a direct stake. At a $630M market cap and clear funding runway, TMQ offers a tactical entry for investors who believe the federal buy-in will accelerate permitting, financing and offtake conversations. This trade plan lays out entry,…
Toyota trades at roughly $196.60 with a market cap near $287.6B, a P/E of about 8.6 and a 2.75% yield. Fundamentals and technicals point to an intact uptrend while AI-driven charging, strategic mobility investments, and a favorable currency backdrop are potential catalysts. This is a long trade idea with a 180-trading-day horizon, defined entry, st…
Micron's unique exposure to HBM and hyperscaler cloud DRAM, record margins, and outsized free cash flow make it the logical beneficiary of an ongoing memory supercycle. This trade idea lays out a mid-term long with concrete entry, stop, and target levels, plus catalysts and the key risks that would invalidate the thesis.
Ormat Technologies' mix of geothermal baseload generation, a rising energy storage services business, and recent project announcements make the stock a buy. Valuation looks reasonable relative to the growth story, and near-term catalysts - including commercial deployments and PPAs - can re-rate the shares. Trade plan targets $125 with a $95 stop fo…
Boeing's share price is trading cheaper after a delivery slowdown headline, but the core drivers - rising 737 output, a large defense backlog and improving engine supply - argue for a tactical long. This trade targets a mid-term rebound as supply-side kinks resolve and markets re-rate the stock.
Golar LNG is entering a new growth chapter driven by multiple long-term FLNG charters and the imminent deployment of a fourth FLNG (MKII) to Argentina. With a roughly $13.7 billion earnings backlog already contracted and a market cap near $5.2 billion, the stock offers an asymmetric risk-reward into 2027-2028 as charter revenues start to ramp. We u…
Kioxia's headline-grabbing margin prints have created expectations that are unlikely to persist. This trade idea buys a return to normalized profitability - not the peak 75% margin - via a mid-term swing where durable product demand and easing channel destocking should support the stock.
CrowdStrike's recent quarter showed a 26% revenue acceleration and record adjusted net income, turning the AI security narrative into tangible ARR leverage. I am upgrading to a Buy and laying out an actionable trade: entry at $226.50, stop at $195.00 and a long-term target of $320.00 (180 trading days).
Okta's recent quarterly beat and AI-driven bookings momentum validate the cybersecurity identity narrative. The stock is in a technical breakout, but the valuation is priced for growth. Buy on a disciplined entry with a clear stop and mid-term target while monitoring conversion of bookings into recurring revenue and competitive pressure.
PayPal fell after a $60.50 takeover proposal from Stripe, Advent and Block was withdrawn on 08/28/2026. The sell-off creates a low-risk entry into a business with $486B TPV (Q2), improving FCF and sub-12x earnings valuation. This trade targets a re-test of the prior bid and operational upside while keeping a tight stop to limit downside risk.
AT&T's latest acquisitions and bolt-on integrations have produced incremental revenue and margin lift that the market has mostly underappreciated. The business still faces legacy headwinds, but near-term catalysts and an attractive yield create a favorable risk/reward for a swing trade. Entry $17.50, target $20.50, stop $16.00.
Ondas (ONDS) is entering a clear execution phase: large government and border-security orders, an accretive Cyberhawk buy, and raised 2026 revenue targets create a path to materially higher top-line figures. Market skepticism (high short interest, negative FCF) keeps volatility elevated, but a tactical long with strict risk controls aims to capture…
IREN just got cheaper after a 15% pullback following an earnings miss. The company controls renewable-rich capacity, has secured multibillion-dollar contracts and is already delivering AI compute to hyperscalers. This trade targets a re-rating as deployments accelerate and short interest unwinds — with a clearly defined entry, stop and target for a…
Dollar General is a durable discount retailer with steady cash flow, a $27.1B market cap, and improving same-store sales. Recent guidance upgrades and a $700M buyback are supportive, but at roughly 16x earnings and $123 per share the stock offers limited upside. This trade recommends a mid-term (45 trading days) short/swing with a clear entry, stop…
Constellium's shares are still trading like the company is stuck on an old, cyclical earnings base. Recent contract wins, a $300M buyback, stronger free cash flow ($218M in the latest reported period) and an improving cost/footprint story argue for a mid-term re-rating. We present an actionable long trade with an entry at $26.52, a stop at $23.50 a…
Tilray (TLRY) carries meaningful short exposure (roughly 18.4M shares short, ~13.8% of float) against a float of 133.2M and multi-million average daily volume. With positive top-line momentum in FY2026, constructive consumer beverage and distribution news, and technicals sitting near short-term support, the stock looks set for a volatile upside mov…
Sabine Royalty Trust (SBR) is a cash-flowing royalty trust trading at $76.25 with a current yield north of 6%. Recent distribution cadence and production prints show higher oil and gas receipts as commodity prices firm amid ongoing supply shocks. The combination of an attractive yield, improving distributions, and supportive technicals gives a favo…
Galaxy Digital (GLXY) offers an asymmetric trade: current market pricing ($22.92, market cap ~$8.96B) embeds downside from crypto volatility and corporate losses, but a Helios-driven 2031 valuation narrative plus improving technicals and structural businesses (digital assets + AI-ready data centers) support a high-conviction long. Entry $23.00, sto…
Nexans looks like a classic 'plateau before payoff' setup: near-term volumes and margins appear constrained, but backlog composition and exposure to grid modernization create a high-conviction mid-term asymmetric trade. Enter on weakness, use a tight stop, and target re-rating as project awards and margin recovery show through.
DSV's recent operational updates point to a faster-than-expected integration of Schenker assets and improving profitability trends. We upgrade to a buy and lay out a mid-term trade with defined entry, stop and target levels that balance upside from margin improvement against integration and macro risks.
AXT's share-price correction after an extraordinary rally and a dilutive follow-on offering has created a measurable risk-reward for speculative, mid-horizon traders. The business controls the lion's share of the indium phosphide substrate market and stands to benefit from structural AI data center demand, but valuation remains extreme and executio…
SLB is trading near multi-month highs but the setup still favors a tactical long. Strong demand for energy security, a surging digital/data-centers business, and healthy cash flow create a constructive risk/reward. This trade idea lays out a clear entry at $58.29, a stop at $53.00 and a $72.00 target over a 180-trading-day horizon.
Kazia Therapeutics (KZIA) is a small-cap oncology developer trading at a $155M market cap. Positive case reports for paxalisib in triple-negative breast cancer (TNBC) and an ongoing GBM regulatory pathway have created a binary, high-volatility setup. For traders willing to accept clinical risk and potential dilution, a speculative long entry near $…
Kelly Partners (KPGHF) trades like a small-cap roll-up with improving technicals, manageable short interest and thin liquidity. We like a tactical long into likely M&A-driven re-rating. Entry $3.46, stop $2.60, target $5.00; mid-term trade (45 trading days).
